1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global DNA Repair Drugs Market
4. Market Overview
    4.1. Introduction
        4.1.1. Product Definition
        4.1.2. Industry Evolution / Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global DNA Repair Drugs Market Analysis and Forecast, 2017-2031
5. Key Insights
    5.1. Technological Advancements
    5.2. Disease Prevalence & Incidence Rate Globally With Key Countries
    5.3. Pipeline Analysis
    5.4. Regulatory Scenario by Region/Globally
    5.5. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)
6. Global DNA Repair Drugs Market Analysis and Forecast, by Drug Type
    6.1. Introduction & Definition
    6.2. Key Findings/Developments
    6.3. Market Value Forecast, by Drug Type, 2017-2031
        6.3.1. PARP Inhibitors
        6.3.2. Alkylating Agents
        6.3.3. Others
    6.4. Market Attractiveness Analysis, by Drug Type
7. Global DNA Repair Drugs Market Analysis and Forecast, by Dosage Form
    7.1. Introduction & Definition
    7.2. Key Findings/Developments
    7.3. Market Value Forecast, by Dosage Form, 2017-2031
        7.3.1. Breast Cancer
        7.3.2. Ovarian Cancer
        7.3.3. Lung Cancer
        7.3.4. Head and Neck Cancer
        7.3.5. Others
    7.4. Market Attractiveness Analysis, by Dosage Form
8. Global DNA Repair Drugs Market Analysis and Forecast, by Dosage Form
    8.1. Introduction & Definition
    8.2. Key Findings/Developments
    8.3. Market Value Forecast, by Dosage Form, 2017-2031
        8.3.1. Tablets
        8.3.2. Capsules
        8.3.3. Injectables
    8.4. Market Attractiveness Analysis, by Dosage Form
9. Global DNA Repair Drugs Market Analysis and Forecast, by Distribution Channel
    9.1. Introduction & Definition
    9.2. Key Findings/Developments
    9.3. Market Value Forecast, by Distribution Channel, 2017-2031
        9.3.1. Retail Pharmacies
        9.3.2. Hospital Pharmacies
        9.3.3. Online Pharmacies
    9.4. Market Attractiveness Analysis, by Distribution Channel
10. Global DNA Repair Drugs Market Analysis and Forecast, by Region
    10.1. Key Findings
    10.2. Market Value Forecast, by Region, 2017-2031
        10.2.1. North America
        10.2.2. Europe
        10.2.3. Asia Pacific
        10.2.4. Latin America
        10.2.5. Middle East & Africa
    10.3. Market Attractiveness By Country/Region
11. North America DNA Repair Drugs Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast, by Drug Type, 2017-2031
        11.2.1. PARP Inhibitors
        11.2.2. Alkylating Agents
        11.2.3. Others
    11.3. Market Value Forecast, by Dosage Form, 2017-2031
        11.3.1. Breast Cancer
        11.3.2. Ovarian Cancer
        11.3.3. Lung Cancer
        11.3.4. Head and Neck Cancer
        11.3.5. Others
    11.4. Market Value Forecast, by Dosage Form, 2017-2031
        11.4.1. Tablets
        11.4.2. Capsules
        11.4.3. Injectables
    11.5. Market Value Forecast, by Distribution Channel, 2017-2031
        11.5.1. Retail Pharmacies
        11.5.2. Hospital Pharmacies
        11.5.3. Online Pharmacies
    11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        11.6.1. U.S.
        11.6.2. Canada
    11.7. Market Attractiveness Analysis
        11.7.1. By Drug Type
        11.7.2. By Dosage Form
        11.7.3. By Dosage Form
        11.7.4. By Distribution Channel
        11.7.5. By Country/Sub-region
12. Europe DNA Repair Drugs Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Drug Type, 2017-2031
        12.2.1. PARP Inhibitors
        12.2.2. Alkylating Agents
        12.2.3. Others
    12.3. Market Value Forecast, by Dosage Form, 2017-2031
        12.3.1. Breast Cancer
        12.3.2. Ovarian Cancer
        12.3.3. Lung Cancer
        12.3.4. Head and Neck Cancer
        12.3.5. Others
    12.4. Market Value Forecast, by Dosage Form, 2017-2031
        12.4.1. Tablets
        12.4.2. Capsules
        12.4.3. Injectables
    12.5. Market Value Forecast, by Distribution Channel, 2017-2031
        12.5.1. Retail Pharmacies
        12.5.2. Hospital Pharmacies
        12.5.3. Online Pharmacies
    12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        12.6.1. Germany
        12.6.2. U.K.
        12.6.3. France
        12.6.4. Italy
        12.6.5. Spain
        12.6.6. Rest of Europe
    12.7. Market Attractiveness Analysis
        12.7.1. By Drug Type
        12.7.2. By Dosage Form
        12.7.3. By Dosage Form
        12.7.4. By Distribution Channel
        12.7.5. By Country/Sub-region
13. Asia Pacific DNA Repair Drugs Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Drug Type, 2017-2031
        13.2.1. PARP Inhibitors
        13.2.2. Alkylating Agents
        13.2.3. Others
    13.3. Market Value Forecast, by Dosage Form, 2017-2031
        13.3.1. Breast Cancer
        13.3.2. Ovarian Cancer
        13.3.3. Lung Cancer
        13.3.4. Head and Neck Cancer
        13.3.5. Others
    13.4. Market Value Forecast, by Dosage Form, 2017-2031
        13.4.1. Tablets
        13.4.2. Capsules
        13.4.3. Injectables
    13.5. Market Value Forecast, by Distribution Channel, 2017-2031
        13.5.1. Retail Pharmacies
        13.5.2. Hospital Pharmacies
        13.5.3. Online Pharmacies
    13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        13.6.1. China
        13.6.2. Japan
        13.6.3. India
        13.6.4. Australia & New Zealand
        13.6.5. Rest of Asia Pacific
    13.7. Market Attractiveness Analysis
        13.7.1. By Drug Type
        13.7.2. By Dosage Form
        13.7.3. By Dosage Form
        13.7.4. By Distribution Channel
        13.7.5. By Country/Sub-region
14. Latin America DNA Repair Drugs Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast, by Drug Type, 2017-2031
        14.2.1. PARP Inhibitors
        14.2.2. Alkylating Agents
        14.2.3. Others
    14.3. Market Value Forecast, by Dosage Form, 2017-2031
        14.3.1. Breast Cancer
        14.3.2. Ovarian Cancer
        14.3.3. Lung Cancer
        14.3.4. Head and Neck Cancer
        14.3.5. Others
    14.4. Market Value Forecast, by Dosage Form, 2017-2031
        14.4.1. Tablets
        14.4.2. Capsules
        14.4.3. Injectables
    14.5. Market Value Forecast, by Distribution Channel, 2017-2031
        14.5.1. Retail Pharmacies
        14.5.2. Hospital Pharmacies
        14.5.3. Online Pharmacies
    14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        14.6.1. Brazil
        14.6.2. Mexico
        14.6.3. Rest of Latin America
    14.7. Market Attractiveness Analysis
        14.7.1. By Drug Type
        14.7.2. By Dosage Form
        14.7.3. By Dosage Form
        14.7.4. By Distribution Channel
        14.7.5. By Country/Sub-region
15. Middle East & Africa DNA Repair Drugs Market Analysis and Forecast
    15.1. Introduction
        15.1.1. Key Findings
    15.2. Market Value Forecast, by Drug Type, 2017-2031
        15.2.1. PARP Inhibitors
        15.2.2. Alkylating Agents
        15.2.3. Others
    15.3. Market Value Forecast, by Dosage Form, 2017-2031
        15.3.1. Breast Cancer
        15.3.2. Ovarian Cancer
        15.3.3. Lung Cancer
        15.3.4. Head and Neck Cancer
        15.3.5. Others
    15.4. Market Value Forecast, by Dosage Form, 2017-2031
        15.4.1. Tablets
        15.4.2. Capsules
        15.4.3. Injectables
    15.5. Market Value Forecast, by Distribution Channel, 2017-2031
        15.5.1. Retail Pharmacies
        15.5.2. Hospital Pharmacies
        15.5.3. Online Pharmacies
    15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        15.6.1. GCC Countries
        15.6.2. South Africa
        15.6.3. Rest of Middle East & Africa
    15.7. Market Attractiveness Analysis
        15.7.1. By Drug Type
        15.7.2. By Dosage Form
        15.7.3. By Application
        15.7.4. By Distribution Channel
        15.7.5. By Country/Sub-region
16. Competition Landscape
    16.1. Market Player – Competition Matrix (By Tier and Size of Companies)
    16.2. Market Share Analysis, by Company (2021)
    16.3. Company Profiles
        16.3.1. AstraZeneca plc
            16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.1.2. Product Portfolio
            16.3.1.3. Financial Overview
            16.3.1.4. SWOT Analysis
            16.3.1.5. Strategic Overview
        16.3.2. Clovis Oncology
            16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.2.2. Product Portfolio
            16.3.2.3. Financial Overview
            16.3.2.4. SWOT Analysis
            16.3.2.5. Strategic Overview
        16.3.3. GlaxoSmithKline plc
            16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.3.2. Product Portfolio
            16.3.3.3. Financial Overview
            16.3.3.4. SWOT Analysis
            16.3.3.5. Strategic Overview
        16.3.4. Pfizer Inc.
            16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.4.2. Product Portfolio
            16.3.4.3. Financial Overview
            16.3.4.4. SWOT Analysis
            16.3.4.5. Strategic Overview
        16.3.5. Merck & Co. Inc.
            16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.5.2. Product Portfolio
            16.3.5.3. Financial Overview
            16.3.5.4. SWOT Analysis
            16.3.5.5. Strategic Overview
        16.3.6. Novartis AG
            16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.6.2. Product Portfolio
            16.3.6.3. Financial Overview
            16.3.6.4. SWOT Analysis
            16.3.6.5. Strategic Overview
        16.3.7. Johnson & Johnson
            16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.7.2. Product Portfolio
            16.3.7.3. Financial Overview
            16.3.7.4. SWOT Analysis
            16.3.7.5. Strategic Overview
        16.3.8. Bristol Myers Squibb Company
            16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.8.2. Product Portfolio
            16.3.8.3. Financial Overview
            16.3.8.4. SWOT Analysis
            16.3.8.5. Strategic Overview
        16.3.9. Onxeo
            16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.9.2. Product Portfolio
            16.3.9.3. Financial Overview
            16.3.9.4. SWOT Analysis
            16.3.9.5. Strategic Overview
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


 
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			